Omalizumab is a humanized murine monoclonal antibody directed toward a portion of the
IgE indicated in Europe for the treatment of severe persistent allergic asthma, inadequately …

BACKGROUND: Omalizumab is a recombinant humanized anti-IgE monoclonal antibody
indicated as an add-on treatment for severe allergic asthma, inadequately controlled despite …

Omalizumab is a humanized monoclonal anti-immunoglobulin E (IgE) antibody indicated in
Europe for the treatment of uncontrolled severe persistent allergic (IgE-mediated) asthma …

Objectives: The aim of this study was to assess the stability of the effectiveness of
omalizumab as add-on treatment in 11 patients with severe persistent allergic asthma …

Introduction: Efficacy and safety of omalizumab in patients with severe allergic asthma has
been established in both randomized controlled trials and real-life studies Aim: To evaluate …

Background Omalizumab was introduced in Malta in 2011. To date, no local data have been
published. Objective To obtain baseline characteristics of our local cohort, determine …

Background: A recombinant humanized anti-IgE mAb, omalizumab, forms complexes with
free IgE, blocking its interaction with mast cells and basophils; as a consequence, it might be …

Omalizumab, a monoclonal antibody that targets circulating IgE, is approved as add-on
therapy for adult and adolescent patients with severe allergic asthma in the EU and …

Omalizumab was the first, and for a long time the only available monoclonal antibody for the
add-on treatment of severe allergic asthma. In particular, omalizumab selectively targets …

Objective. Omalizumab is a biological treatment for difficult-to-treat allergic asthma. Its
mechanism of action relies on impeding the binding of immunoglobulin E (IgE) to specific …